Veraxa Biotech Holding AG

VRXA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.95

+$0.06 · +3.17%

Aug 21, 4:00 PM ET

Historical prices · Market data may be delayed.

Company profile

Company website

Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]

Industry: Biotechnology
Sector: Healthcare
Headquarters: DE
CEO: Christoph Antz
Listed since: Jun 9, 2026
Employees: 8

Market position

Day range

Current $1.95

$1.86$2.00

52-week range

Current $1.95

$1.70$27.36

Open: $1.86
Previous close: $1.89
Volume: 80.18K; 0.2× average
Average volume: 403.81K; Average daily volume
Market cap: 275.75M USD
Beta: 0.26; Market reference 1
50-day average: $3.5715; -45.40% below average
200-day average: $9.2316; -78.88% below average

VRXA news

globenewswire.comJul 29, 2026

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

ZURICH, SWITZERLAND, July 29, 2026 (GLOBE NEWSWIRE) -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided an update on its core patent portfolio. During…

Read source

globenewswire.comJul 27, 2026

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VERAXA Biotech's and OmniAb's bispecific ADC program VXA-222 advances into next phase at VERAXA following the achievement of a key technical milestone.

Read source

globenewswire.comJul 27, 2026

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program…

Read source

globenewswire.comJul 24, 2026

VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth

ZURICH, SWITZERLAND , July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, held an Extraordinary General…

Read source

globenewswire.comJul 23, 2026

VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio

ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph Erkel, Ph.D., as…

Read source

globenewswire.comJul 20, 2026

VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan

ZURICH, SWITZERLAND – July 20, 2026 – VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the German regulatory…

Read source